Small-cell lung cancer (SCLC) is an aggressive tumor with a dismal prognosis among primary lung cancers. MicroRNAs (miRNAs) can act as oncogenes or tumor-suppressor genes in human malignancy. The miR-34 family is comprised of tumor-suppressive miRNAs, and its reduced expression by methylation has been reported in various cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the alteration and tumor-suppressive impact of miR-34s in SCLC.
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Introduction
Lung cancer is the leading cause of cancer-related death in the world at present.
Small-cell lung cancer (SCLC) is an aggressive tumor with a dismal prognosis among primary lung cancers and accounts for approximately 13 % of all lung cancers [1, 2] .
Chemotherapy or chemoradiotherapy is generally the treatment of choice for SCLC patients because the clinical features of SCLC include a high rate of metastasis to lymph nodes and distant organs beginning at an early stage. A strong initial response but early acquired resistance to chemotherapeutic agents is a unique feature of SCLC [3, 4] , resulting in a poor prognosis and a 5-year survival rate of only 5 % [5] . Thus, the development of new therapeutic strategies is mandatory.
The understanding of molecular pathogenesis is crucial for the development of new therapeutic strategies for malignant tumors. Of note, the profile of molecular alterations is quite different among the histological subtypes of lung cancer [6] [7] [8] . For example, epidermal growth factor receptor (EGFR) mutations [9] , K-ras mutations and P16 methylation [8] are frequently found in non-small cell lung cancer (NSCLC), but not in SCLC [10] . In contrast, TP53 mutations [8, 11] or RASSF1A methylation [12] is frequently found in SCLC, compared with NSCLC. These results indicate that the molecular pathogenesis differs between SCLC and NSCLC.
Many studies have shown that microRNAs (miRNAs) can act as oncogenes or tumor suppressors and that the widespread alteration of miRNA expression patterns is highly relevant to various human malignancies [13] . In lung cancer, the reduced expression of let-7 [14] or the overexpression of miR-155 [15] is reportedly correlated with the clinical outcome of NSCLC. The members of the miR-34 family consist of three miRNAs (miR-34a, 34b and 34c), the target genes of which are considered to be similar to one another but with some notable differences [17] . miR-34a is located on chromosome 1q36.22, while miR-34b and 34c (miR-34b/c) are located on chromosome 11q23 and are generated by the processing of a single transcript [17] . A previous study indicated that miR-34 methylation was present in NSCLC and was significantly related to an unfavorable clinical outcome [18] . In a functional analysis the introduction of miR-34b/c into NSCLC suppressed the cell proliferation of NSCLC [19] . However, these studies examining the roles of miRNA in lung cancer have been mainly performed for NSCLC, and miRNA alterations and their impact on SCLC have not been investigated.
In this study, we investigated miR-34 methylation in SCLC and found that miR-34b/c was frequently methylated in SCLC, compared with NSCLC. Subsequently, we investigated the biological impact of miR-34b/c methylation on SCLC to understand the role of miR-34b/c in the tumorigenesis of SCLC. with bovine pituitary extract (BPE) and human recombinant epidermal growth factor (EGF). H82, H249, H1048, and SBC5 were treated with 5-aza-2'-deoxycytidine (DAC) (Sigma-Aldrich) at a concentration of 5-10 μM for 6 days, with medium changes on days 1, 3, and 5, to restore gene expression that was reduced by methylation.
Materials and methods

Clinical samples and cell lines
Methylation specific PCR (MSP) assay
Genomic DNA was extracted from cell lines and tissues by standard phenol-chloroform (1:1) extraction or by DNeasy Tissue Kit (Qiagen, Valencia, CA).
DNA was subjected to bisulfate treatment using the EZ DNA Methylation Gold kit (Zymo Research Corp., Irvine, CA) according to the manufacturer's protocol. For malignant pleural effusions, genomic DNA was extracted using QIAamp Circulating
Nucleic Acid kit (Qiagen) and bisulfite conversion was performed using Epitect
Bisulfite kit (Qiagen) according to the manufacturer's protocol. The methylation statuses of miR-34a and 34b/c were determined by MSP assay using specific primers for the methylated and unmethylated forms [20] . The DNA from HBEC 5KT was treated with SssI methyltransferase (New England BioLabs, Beverly, MA) and was used as a positive control for methylated alleles. PCR products were analyzed in 2 % agarose gels and stained with ethidium bromide.
miR-34s expression by quantitative RT-PCR
The miRNA was isolated from cell lines and tissue specimens with TaqMan
MicroRNA Cells-to-CT TM Kit (Ambion, Austin, TX) and mirVana TM miRNA Isolation 
Immunohistochemistry for p53 expression
Abnormality of p53 expression was examined using immunohistochemistry for primary tumors. To detect the p53 protein, we used a monoclonal antibody against human p53 (DAKO-p53, DAKO, Denmark). The routinely formalin-fixed, paraffin-embedded tissue blocks were sectioned at a 4 μm thickness. They were stained by hematoxylin and eosin stain to confirm the presence and intensity of tumor cells and processed for immunohistochemistry (IHC). Tissue sections were deparaffinized with xylene, rehydrated with graded ethanol, and immersed in Tris-buffered saline for IHC.
For p53 scoring, more than ten randomly chosen high power fields were evaluated under an optical microscope and a trained pathologist was defined blindly scored. In this study, p53 mutational status was defined as positive when more than 15 % of cells were positive regardless of the intensity as previously reported [21, 22] .
Plasmid construction and gene transfection
The miR-34b/c or scramble fragment as control was subcloned into pSilencer 4.1-CMV neo Plasmid Vector (Ambion). Four μg of pSilencer 4.1-CMV neo Vector was introduced into SCLC cell lines using Lipofectamine TM 2000 Reagent (Invitogen).
For experiments of transient transfection, cells were collected 72 hours after the transfection. In order to establish stable transfectants, selection of the cells was started 48 hours after the transfection in 6 cm dish with G418 (Invitrogen) antibiotics.
Resistant clones were cloned after 3 weeks of selection.
Colony formation assay for cell proliferation
The in vitro cell proliferation was tested by liquid colony formation assay.
Fifty viable cells were plated onto 6-well plates in triplicate. Cells were cultured and counted 14 days later after staining with 0.1 % crystal violet in 20 % ethanol for 5 minutes at room temperature. The number of visible colonies (> 50 cells) was counted.
Cell migration and invasion assays
Cell migration and invasion ability were established using a Boyden chamber 
Statistical analysis
Statistical analysis was performed using SPSS for Windows version 17.0 (SPSS, Chicago, IL, USA). All of the in vitro experiments were performed at least three times. Data were represented as mean ± standard deviation. The significance of the differences between two groups was determined using the chi-square test and the Mann-Whitney U-test, as appropriate. A 5 % significance level (p < 0.05) was considered statistically significant.
Results
Methylation and expression status of miR-34s
We 
Relationship between methylation and expression in SCLC
The expressions of miR-34a, 34b, and 34c in 11 SCLC cell lines and 6 available SCLC primary tumors (4 methylated and 2 unmethylated cases) were examined using quantitative RT-PCR (Tables I, II ). The expression values of the miR-34s were defined as the ratio of the normalized expression value of SCLC cell lines to that of HBEC 5KT
and that of the primary SCLC tumors to that of individual non-malignant lung tissue with arbitrarily assigned values of 1, respectively. As shown in Table I Regarding miR-34a, no significant difference or tendency was detected (p = 0.107).
This finding may reflect the small sample sizes or the presence of partially methylated cells. One cell line (H2141) with unmethylated miR-34a had very low expression value (0.05) for miR-34a, suggesting the presence of an alternative mechanism for gene silencing.
We also treated 4 cell lines with DAC and found that the expressions of the miR-34s were restored in the methylated SCLC cell lines but not in the unmethylated cell lines (Table III) .
3.3.p53 status in SCLC
p53 is a transcriptional factor for miR-34s. Thus, we examined the correlation between the p53 status and the expressions of miR-34s (Table II) was examined, but no correlation between the p53 status and the expressions of miR-34s was found.
Impact of miR-34b/c on cell proliferation
Because the frequency of methylation was higher in miR-34b/c and because miR-34a methylation in SCLC cell lines was mainly partial methylation but miR-34b/c was heavily methylation, we focused on miR-34b/c for a functional analysis. For this purpose, we established stable transfectans with miR-34b/c and scramble controls for H1048 and SBC5. To examine the anti-proliferative effect of miR-34b/c induction, we performed a colony formation assay for stable transfectants. Cell proliferation was significantly inhibited in the SCLC cells transfected with miR-34b/c, compared with that in the cells that were transfected with a scramble control (50 % inhibition for H1048, p = 0.001; 44 % for SBC5, p< 0.001) (Fig.2) .
Impact of miR-34b/c on cell migration and invasion
To estimate the effect of introducing miR-34b/c on the migration and invasion potential of SCLC, cell migration and invasion potential were examined using a Boyden chamber. Microscopy images of the Boyden chamber assay are shown in Figure 3 .
Migration and invasion were significantly suppressed in miR-34b/c transfectants, compared with control transfectants (migration: 50 % inhibition for H1048, p = 0.051; 54 % for SBC5, p = 0.044; invasion: 33 % inhibition for H1048, p = 0.002; 30 % inhibition for SBC5, p = 0.012).
Protein expression of stable transfectants
To examine the effect of miR-34b/c introduction, we focused on c-MET (both total and phosphorylated types) and CDK6 which were the putative target of miR-34b/c. Western blotting was carried out in SCLC stable transfectants. Total and phosphorylated c-MET and CDK6 expressions were down-regulated in the SCLC cell lines examined. CDK6 tended to be down-regulated by the miR-34b/c in cell lines whose native protein expression was present (Figure 4 ).
Discussion
In this study, we found that miR-34b/c methylation was a frequent alteration of SCLC. As a result, miR-34b/c expression was reduced in SCLC, causing tumor cell proliferation and invasiveness. Our results also indicated that miR-34b/c methylation is the early event for tumorigenesis of SCLC because there was no difference in frequency between surgically resected tumors supposed to be early stage and malignant pleural effusions considered to be advanced stage. In addition to lung cancer, miR-34b/c methylation has been reported in various kinds of malignant tumors including colorectal and ovarian cancers [20, 24] . We previously reported the methylation and function of miR-34b/c in malignant pleural mesothelioma [25] ; the same established methodology was also used in the present study. p53 is a transcriptional factor for miR-34s. The p53 mutation has been reported in various cancers, including lung cancer. However, the effect of p53 mutation on the expression and methylation of miR-34b/c remains uncertain. In ovarian cancer, miR-34a methylation and p53 mutation are not associated. Corney and associates reported that no direct correlation was observed between miR-34 methylation status and miR-34 expression levels. In addition, p53 mutation has no effect on miR-34b/c methylation in ovarian cancer [24] . In the SCLC cell lines that were examined in the present study, 10 out of 11 cell lines carried a p53 mutation, but the expression levels of the miR-34s
varied and were correlated with the methylation status. In primary tumors, while the p53 mutational status was determined using immunohistochemistry [21, 22] , the relationship among the expression and methylation of miR-34b/c and p53 mutation was similar to that in the cell lines. Our data suggest that miR-34 expression was not completely silenced in the p53-altered cases and that methylation may contribute more strongly to the expressions of miR-34s.
Antitumor effects, including the inhibition of cell proliferation, migration, and invasion, were observed with the introduction of miR-34b/c. In general, miRNA has multiple target mRNAs, and c-Met is a well-known target molecule of miR-34b/c [16, 17] . c-Met and its ligand hepatocyte growth factor (HGF) have been shown to be involved in cell proliferation, invasion, and angiogenesis [26, 27] . A previous study found that the c-Met/HGF pathway was functional in SCLC, indicating in vitro that the c-MET/HGF axis may be a promising target for SCLC [27, 28] . Our results, together with those of previous reports, strongly suggest that miR-34b/c plays an important role in the pathogenesis of SCLC and may be a useful therapeutic target for SCLC.
In SCLC, the methylation of miR-34a was not a frequent event compared with that of miR-34b/c, but its expression was low compared with that in non-malignant lung tissue. The degree of reduction in miR-34a expression was similar to that of miR-34b/c in some SCLC cell lines, suggesting that miR-34a silencing may also be involved in the pathogenesis of SCLC, although the mechanism of silencing has not been clearly elucidated. Further study on the role of miR-34a in SCLC is warranted.
In conclusion, our findings showed that miR-34b/c is more frequently methylated in SCLC than in NSCLC, resulting in the down-regulation of miR-34b/c. 
Table I
The relative expressions and methylation status of miR-34s in 11 SCLC cell lines.
Mut, mutation; Wt, wild type; NA, not available; M, methylated; U, unmethylated;
M/U, partially methylated *, miR-34s relative expression values are relative expression values compared with those of HBEC 5KT, which are defined as 1.
Table II
The relative expressions and methylation status of miR-34s in 6 available SCLC primary tumors.
LD, limited disease; ED, extensive disease; Mut, mutation; Wt, wild type; NA, not available; M, methylated; U, unmethylated *, p53 mutational status is as positive if more than 15 % of nuclei are stained.
**, miR-34s relative expression values are relative expression values compared with those of each non-malignant tissue, which are defined as 1.
Table III
The fold change of miR-34s expression after DAC treatment. 
